Company Information

  

Address: ONE KENDALL SQUARE
BUILDING 200, STE. 2203 
City: CAMBRIDGE 
State: MA 
Zip Code: 02139 
Telephone: (857) 999-0075 

Description of Business

Primary SIC Code: 2834
(As filed with the SEC)  

We are a clinical stage pharmaceutical company focused on the discovery, development and commercialization of small molecule protease inhibitors for diseases with significant unmet need. Our first product candidates are inhibitors of plasma kallikrein being developed for two indications: hereditary angioedema ("HAE") and diabetic macular edema ("DME"). We apply our insights into the chemistry of proteases and, with our current programs, the biology of the plasma kallikrein system, to develop small molecule inhibitors with high selectivity, potency and bioavailability that we believe will make them successful treatments for disease. We have created a structurally diverse portfolio of oral plasma kallikrein inhibitors and advanced multiple drug candidates into Phase 1 clinical trials for HAE in order to create what we believe will be best-in-class oral therapies.  ... More ...  

Per Share Overview

Date 12-mos Rolling EPS Dividend P/E Ratio
07/2018-1.49NAN/E
04/2018-1.53NAN/E
01/2018-0.46NAN/E
10/20177.18NA1.77
04/2017-4.47NAN/E
09/2016103.88NA0.06

Key Financial Ratios and Statistics

FYE: 04/30

Profitability 2018 Leverage 2018
Net Inc/Comm Equity-0.16Total Liab/Total Assets0.56
Net Inc/Total Assets-0.26Total Liab/Inv Cap0.90
Net Inc/Inv Cap-0.42Total Liab/Comm Equity0.34
Pretax Inc/Net Sales-1.88Interest Coverage RatioNA
Net Inc/Net Sales-1.88Curr Debt/Equity0.01
Cash Flow/Net Sales1.26LTD/Equity0.00
SG&A/NetSales1.06Total Debt/Equity0.01
Asset Utilization   Liquidity  
Net Receivables Turnover1.79Quick Ratio2.56
Inventory TurnoverNACurrent Ratio2.56
Inventory Day SalesNANet Rec/Curr Assets0.12
Net Sales/Work Cap0.23Inv/Curr AssetsNA
Net Sales/PP&E4.57  

Income Statement (Millions)

  4/30/2018 1/31/2018 10/31/2017 7/31/2017
Total Revenues(Net Sales) 4.84 2.33 1.13 0.10
Cost of Goods Sold NA NA NA NA
Selling & Admin Exps 1.96 2.13 2.70 2.07
Operating Income -2.97 -4.35 -5.94 -5.45
Interest Exp NA NA NA NA
Pretax Income -0.66 -5.23 -4.99 -4.93
Other Income 2.31 -0.89 0.95 0.53
Net Income Bef Extraordinary ... NA NA NA NA
Net Income -0.66 -5.23 -4.99 -4.93

Balance Sheet (Millions)

Assets 4/30/2018 1/31/2018 10/31/2017 7/31/2017
Cash & Short Term Investments 51.06 58.68 28.13 26.46
Receivables - Total 6.83 5.03 4.61 2.90
Inventories - Total NA NA NA NA
Total Current Assets 59.38 65.71 34.14 30.19
Net Property, Plant & Equipment 1.84 0.77 0.60 0.59
Total Assets 61.39 66.66 34.74 30.78
Liabilities        
Accounts Payable 4.52 3.87 3.29 3.64
Debt in Current Liabilities 0.22 0.22 0.22 0.20
Total Current Liabilities 23.22 24.08 3.51 3.84
Long-Term Debt 0.06 0.12 0.15 0.21
Total Liabilities 34.14 38.09 3.66 4.05
Stockholder's Equity        
Minority Interest NA NA NA NA
Preferred Stock NA NA NA NA
Common Stock 0.01 0.01 0.01 0.01
Retained Earnings -71.66 -71.00 -65.77 -60.78
Treasury Stock NA NA NA NA
Total Stockholders' Equity 27.25 28.57 31.08 26.73
Total Liabilities and Stockholders' Equity 61.39 66.66 34.74 30.78

Cash Flow Summary (Millions)

Categories 4/30/2018 1/31/2018 10/31/2017 7/31/2017
Net Cash Provided by Operating Activities -5.96 28.22 -7.26 -4.45
Net Cash Provided by Investing Activities -1.08 -0.18 -0.05 -0.11
Net Cash Provided by Financing Activities -0.01 -0.05 9.05 0.00

Annual Summary Data (Millions)

Year Sales Net Income EPS
04/20130.42-5.68--
04/20140.03-13.36--
04/20150.03-24.85--
04/20171.50-18.60-4.47
04/20188.39-15.80-1.53
Growth Rates112.07----

Stock Ownership

Type Date(Q,M) No. Owners Shares Held (000s) % Own
Institutional06/30/18286,31650.21




Report Date : 9/17/2018

Powered By Edgar Online © 2018EDGAR®Online, a division of Donnelley Financial Solutions. EDGAR® is a federally registered trademark of the U.S. Securities and Exchange Commission. EDGAR Online is not affiliated with or approved by the U.S. Securities and Exchange Commission.